Last reviewed · How we verify
CHONDRON
CHONDRON is an autologous chondrocyte-based cell therapy that regenerates cartilage tissue by implanting a patient's own expanded cartilage cells into damaged joint areas.
CHONDRON is an autologous chondrocyte-based cell therapy that regenerates cartilage tissue by implanting a patient's own expanded cartilage cells into damaged joint areas. Used for Cartilage defects of the knee, Osteoarthritis of the knee.
At a glance
| Generic name | CHONDRON |
|---|---|
| Also known as | Autologous cultured Chondrocyte |
| Sponsor | Sewon Cellontech Co., Ltd. |
| Drug class | Autologous cell therapy |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
CHONDRON involves harvesting healthy cartilage cells (chondrocytes) from a patient, expanding them in culture, and reimplanting them into areas of cartilage defect or osteoarthritis. This approach aims to restore cartilage structure and function by leveraging the patient's own cells to promote tissue regeneration and reduce joint degeneration.
Approved indications
- Cartilage defects of the knee
- Osteoarthritis of the knee
Common side effects
- Injection site pain or swelling
- Infection at implantation site
- Graft failure or inadequate integration
Key clinical trials
- Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment (PHASE3)
- Effectiveness and Safety of Knee Cartilage Lesion Treatment Using CartiONE: 1-to-13 Year Follow-up.
- IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee. (PHASE1, PHASE2)
- The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) (PHASE4)
- The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy (PHASE4)
- Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle (PHASE3)
- the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee
- Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHONDRON CI brief — competitive landscape report
- CHONDRON updates RSS · CI watch RSS
- Sewon Cellontech Co., Ltd. portfolio CI